NEW HAVEN, Conn., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence…
The pricing announcement from the Center for Medicare Services became effective on October 1, 2024, and allows BioStem to begin…
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on…
The planned registration program consists of two double-blind, placebo-controlled multicenter Phase 3 trials, FASCINATE-3 and FASCINIT, to evaluate the safety…
Adds Proven Kidney-on-Chip Technology to Its Pioneering Bio-AI PlatformBOSTON and TEL AVIV, Israel, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Quris-AI…
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics…
BRECKENRIDGE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Breckenridge Distillery, one of the most-awarded craft distilleries in the U.S. and a…
NEW YORK and LONDON and SAO PAOLO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Claritas NucMed Tech Brazil S.A. (“Claritas NucMed…
Randomized, controlled study will be first in personalized spacing evidence to include patients who have a prostate cancer recurrence after…